New Delhi: The global digital respiratory devices market was valued at US$ 43 Billion in 2022 and is expected to expand at a CAGR of 25% from 2022 to 2032. The increased frequency of respiratory disorders has pushed for advancements in the production of breathing equipment.
Over the recent decade, several novel medications for the treatment of COPD and other respiratory illnesses such as asthma have been introduced. With more items in the pipeline, the digital respiratory devices market will have more room for growth, especially because demand for respiratory devices has increased due to the COVID-19 pandemic.
The pandemic issue has resulted in accelerated medicine approval and product launch, which is the most popular among pharmaceutical producers. The COVID-19 has resulted in manufacturing relationships between healthcare and non-healthcare companies. To satisfy rising demand, manufacturers are ramping up production of breathing equipment. These developments are indicative of positive progress. The global respiratory devices market is expected to develop at a 25% CAGR through 2032, according to Fact.MR.
Rising Inclination towards Combination Medicines anticipated driving the Global Market
The usage of combination treatments for COPD and asthma therapy has steadily increased. Patients choose combination treatments due to benefits such as higher effectiveness, greater dependability in difficult patients, and advantageous therapy reimbursement policies.
A crucial reason for digital respiratory device makers is the growing inclination for combination medicines such as triple combination therapy. Combination therapy is regarded as a dependable source of treatment for people suffering from complicated respiratory illnesses. Furthermore, excellent reimbursement schemes have encouraged the use of these medicines.
Competitive Landscape
Regional developments through mergers and alliances, as well as product releases, are some of the primary methods employed by market participants.
Recent Developments:
-
In September 2021, Adherium Limited, a market leader in respiratory eHealth, remote monitoring, and data management, announced that the FDA’s 510(k) approval has allowed it to begin selling its first, next-generation Hailie Sensor, which includes physiological measures for tracking the use of asthma and COPD medications.
-
In November 2019, Propeller Health expanded their pharmacy refill app to cover CVS, Rite-Aid, Kroger, and Walmart pharmacies.
-
In January 2019, Propeller Health also launched My Drugstore, an in-app service in collaboration with Walgreens that allows clients to manage their medication refills for COPD and asthma and locate a nearby pharmacy.
Link to the Report
